trending Market Intelligence /marketintelligence/en/news-insights/trending/zbwecfyantfbirjowwsz8q2 content esgSubNav
In This List

MabVax to delist from Nasdaq

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

MabVax to delist from Nasdaq

MabVax Therapeutics Holdings Inc. said it received a delisting determination from Nasdaq Stock Market LLC.

MabVax directors previously decided against planning to regain compliance with the exchange's listing rules.

MabVax was not in compliance with the exchange's listing requirements for stockholders' equity and periodic report filings. MabVax underwent a Securities and Exchange Commission investigation regarding its financial and registration statements.

The San Diego-based biopharmaceutical company will not appeal the decision, and its common stock will be suspended from the Nasdaq Capital Market on July 11.